This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Value ETF Investing to Shine as Sector Rotation Looks Likely?
by Sanghamitra Saha
As rising rates are in the cards, value stocks are likely to take a center stage in the near term.
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
Can Biotech ETFs Gain From Positive Booster Update?
by Sweta Jaiswal, FRM
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs
by Sweta Jaiswal, FRM
The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.
Biotech ETFs to Benefit From Latest Booster Update
by Sweta Jaiswal, FRM
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Biogen's Alzheimer's Drug Approval Puts Biotech ETFs in Spotlight
by Sweta Jaiswal, FRM
The FDA's approval of the first new drug to treat Alzheimer's disease in about 20 years has attracted investors' attention toward the biotech sector while sparking new controversies.
4 ETF Areas Surged Last Week
by Sanghamitra Saha
These four ETF areas were winners last week.
Top-Performing Biotech ETFs of Last Week
by Sweta Killa
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
by Sweta Jaiswal, FRM
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Moderna ETFs to Gain on Positive 'Real-World' Study Data
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress by Moderna (MRNA) grabs investors' attention.
Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?
by Sweta Jaiswal, FRM
Positive coronavirus vaccine update from Moderna (MRNA) has hogged investors' attention.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
by Sweta Jaiswal, FRM
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Moderna ETFs to Shine on Vaccine News as Outbreak Worsens
by Sweta Jaiswal, FRM
Positive coronavirus vaccine progress from Moderna (MRNA) has hogged investors' attention.
Moderna Expects COVID-19 Vaccine Data in November: ETFs to Gain
by Sweta Jaiswal, FRM
Positive comment on coronavirus vaccine progress from Moderna's (MRNA) CEO during The Wall Street Journal's annual Tech Live conference has gained investors attention and raised vaccine optimism.
Healthcare ETFs, Stocks That Gained Double Digits Last Week
by Sweta Killa
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
4 Best-Performing Sector ETFs of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones and the Nasdaq Composite have lost about 0.6%, 0.03% and 0.6%, respectively, past week.
Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Why Small-Cap Biotech ETFs Are Good Long-Term Bets
by Sanghamitra Saha
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.
Moderna Turns Red Hot: Biotech ETFs to Bet On
by Sweta Killa
Moderna skyrocketed 245% since it announced its COVID-19 vaccine candidate mRNA-1273 on Feb 10. The solid run is likely to continue as most of the analysts are optimistic on the stock.
Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine
by Sweta Jaiswal, FRM
Moderna plans to begin the Phase 3 study of mRNA-1273 this month.